Tobin Juvenal Sells 9,050 Shares of Castle Biosciences (NASDAQ:CSTL) Stock

Castle Biosciences, Inc. (NASDAQ:CSTL) insider Tobin Juvenal sold 9,050 shares of Castle Biosciences stock in a transaction on Tuesday, August 25th. The shares were sold at an average price of $35.04, for a total value of $317,112.00. Following the completion of the sale, the insider directly owned 66,914 shares of the company’s stock, valued at $2,344,666.56. This trade represents a 11.91% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Castle Biosciences Trading Up 0.5%

Shares of CSTL traded up $0.18 during trading hours on Thursday, hitting $34.26. 251,211 shares of the stock traded hands, compared to its average volume of 405,577. The company has a current ratio of 6.04, a quick ratio of 5.85 and a debt-to-equity ratio of 0.02. Castle Biosciences, Inc. has a 1-year low of $17.72 and a 1-year high of $44.28. The firm has a market capitalization of $1.05 billion, a PE ratio of -51.91 and a beta of 0.98. The business has a fifty day moving average of $26.73 and a 200-day moving average of $25.41.

Castle Biosciences (NASDAQ:CSTL) last announced its quarterly earnings data on Thursday, July 30th. The company reported ($0.07) EPS for the quarter, topping analysts’ consensus estimates of ($0.41) by $0.34. The firm had revenue of $99.86 million during the quarter, compared to analyst estimates of $86.23 million. Castle Biosciences had a negative return on equity of 4.15% and a negative net margin of 5.43%. Analysts expect that Castle Biosciences, Inc. will post -1.29 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the stock. BlackRock Inc. bought a new stake in shares of Castle Biosciences during the second quarter worth $78,513,000. Vanguard Group Inc. lifted its position in Castle Biosciences by 1.3% in the 4th quarter. Vanguard Group Inc. now owns 2,199,829 shares of the company’s stock valued at $85,573,000 after acquiring an additional 27,511 shares in the last quarter. RTW Investments LP acquired a new position in Castle Biosciences in the 4th quarter worth $82,283,000. Principal Financial Group Inc. boosted its stake in Castle Biosciences by 0.7% in the 4th quarter. Principal Financial Group Inc. now owns 1,807,644 shares of the company’s stock worth $70,317,000 after purchasing an additional 13,289 shares during the period. Finally, Dimensional Fund Advisors LP increased its holdings in Castle Biosciences by 7.0% during the 3rd quarter. Dimensional Fund Advisors LP now owns 1,474,089 shares of the company’s stock worth $33,564,000 after purchasing an additional 96,084 shares in the last quarter. Institutional investors own 92.60% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on the stock. BTIG Research boosted their price target on shares of Castle Biosciences from $40.00 to $44.00 and gave the stock a “buy” rating in a research note on Monday, August 3rd. Zacks Research lowered shares of Castle Biosciences from a “strong-buy” rating to a “hold” rating in a report on Tuesday, May 26th. Robert W. Baird set a $36.00 target price on shares of Castle Biosciences in a research report on Friday, July 31st. KeyCorp set a $35.00 price target on Castle Biosciences in a research note on Friday, May 29th. Finally, Weiss Ratings upgraded Castle Biosciences from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, July 31st. One research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $42.00.

About Castle Biosciences

Castle Biosciences, Inc is a molecular diagnostics company specializing in the development and commercialization of prognostic and diagnostic tests for patients with dermatologic conditions. The company’s proprietary portfolio of genomic assays is designed to improve risk assessment and guide clinical decision-making for individuals with skin cancers and other skin-related diseases. By combining genomic data with advanced statistical algorithms, Castle Biosciences seeks to provide actionable insights that help physicians tailor treatment plans and monitoring strategies.

The company’s flagship test, DecisionDx-Melanoma, evaluates the probability of metastasis in patients diagnosed with cutaneous melanoma, supporting more personalized surveillance and therapeutic approaches.